PL3350220T3 - Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania - Google Patents
Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowaniaInfo
- Publication number
- PL3350220T3 PL3350220T3 PL16774748T PL16774748T PL3350220T3 PL 3350220 T3 PL3350220 T3 PL 3350220T3 PL 16774748 T PL16774748 T PL 16774748T PL 16774748 T PL16774748 T PL 16774748T PL 3350220 T3 PL3350220 T3 PL 3350220T3
- Authority
- PL
- Poland
- Prior art keywords
- mystatin
- latent
- applications
- antibodies against
- against pro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562219094P | 2015-09-15 | 2015-09-15 | |
| PCT/US2016/052014 WO2017049011A1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
| EP16774748.4A EP3350220B1 (en) | 2015-09-15 | 2016-09-15 | Anti-pro/latent-myostatin antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3350220T3 true PL3350220T3 (pl) | 2022-01-03 |
Family
ID=57043000
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16774748T PL3350220T3 (pl) | 2015-09-15 | 2016-09-15 | Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania |
| PL21170667.6T PL3922645T3 (pl) | 2015-09-15 | 2016-09-15 | Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21170667.6T PL3922645T3 (pl) | 2015-09-15 | 2016-09-15 | Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10751413B2 (pl) |
| EP (3) | EP3922645B1 (pl) |
| JP (4) | JP7107836B2 (pl) |
| KR (3) | KR102773636B1 (pl) |
| CN (4) | CN113912718B (pl) |
| AU (2) | AU2016323447B2 (pl) |
| BR (1) | BR112018004981A2 (pl) |
| CA (1) | CA3036652A1 (pl) |
| CO (1) | CO2018002703A2 (pl) |
| CY (1) | CY1124619T1 (pl) |
| DK (2) | DK3922645T3 (pl) |
| EA (1) | EA038146B1 (pl) |
| ES (2) | ES2881642T3 (pl) |
| FI (1) | FI3922645T3 (pl) |
| HR (2) | HRP20250666T1 (pl) |
| HU (2) | HUE072064T2 (pl) |
| IL (2) | IL305148A (pl) |
| LT (2) | LT3350220T (pl) |
| MX (5) | MX2018003196A (pl) |
| PL (2) | PL3350220T3 (pl) |
| PT (2) | PT3922645T (pl) |
| RS (2) | RS62330B1 (pl) |
| SI (2) | SI3922645T1 (pl) |
| SM (2) | SMT202100432T1 (pl) |
| WO (1) | WO2017049011A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2014DN10515A (pl) | 2006-03-31 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | |
| MX336725B (es) | 2007-09-26 | 2016-01-28 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
| TWI700293B (zh) | 2008-04-11 | 2020-08-01 | 日商中外製藥股份有限公司 | 重複結合複數個抗原的抗體 |
| KR102568454B1 (ko) | 2010-11-30 | 2023-08-18 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| AU2014250434B2 (en) | 2013-04-02 | 2019-08-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| TWI656133B (zh) | 2014-12-19 | 2019-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法 |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| IL305148A (en) | 2015-09-15 | 2023-10-01 | Scholar Rock Inc | Anti-pro/hidden myostatin antibodies and their uses |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| JP2019504064A (ja) | 2016-01-08 | 2019-02-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| EP3785728A3 (en) * | 2016-06-13 | 2021-04-28 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
| CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| WO2018129395A1 (en) * | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| JP7198757B2 (ja) * | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
| LT3677278T (lt) | 2018-07-11 | 2022-01-10 | Scholar Rock, Inc. | Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas |
| AU2019302679A1 (en) | 2018-07-11 | 2021-02-11 | Scholar Rock, Inc. | High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof |
| TW202043267A (zh) | 2019-01-30 | 2020-12-01 | 美商供石公司 | TGFβ之LTBP複合物專一性抑制劑及其用途 |
| CN110429214B (zh) | 2019-08-07 | 2021-12-07 | 宁德时代新能源科技股份有限公司 | 二次电池的盖组件及二次电池 |
| CN120025435A (zh) | 2019-08-28 | 2025-05-23 | 中外制药株式会社 | 跨物种抗潜伏TGF-β1抗体和使用方法 |
| US20230050148A1 (en) | 2020-01-11 | 2023-02-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| RU2750267C1 (ru) * | 2020-02-07 | 2021-06-25 | Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» | Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата |
| CA3193909A1 (en) | 2020-10-26 | 2022-05-05 | George NOMIKOS | Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| MX2023014840A (es) | 2021-06-23 | 2024-02-12 | Scholar Rock Inc | Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos. |
| KR102836354B1 (ko) * | 2021-11-25 | 2025-07-22 | (주)네오크레마 | 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도 |
| KR102840816B1 (ko) * | 2021-11-25 | 2025-07-31 | (주)네오크레마 | 근아세포의 증식과 근육세포로의 분화를 촉진하는 신규 펩티드 및 이의 용도 |
| EP4518970B1 (en) | 2022-05-04 | 2026-03-25 | Scholar Rock, Inc. | Use of myostatin inhibitor for treating spinal muscular atrophy |
| TW202423419A (zh) | 2022-10-14 | 2024-06-16 | 美商建南德克公司 | 治療脊髓性肌肉萎縮症之方法 |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
| JP2026507882A (ja) | 2023-03-07 | 2026-03-06 | スカラー ロック インコーポレイテッド | 患者の抵抗性又は不応答性癌を治療するためのＴＧＦ－β阻害剤及びその使用 |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE240401T1 (de) | 1989-03-21 | 2003-05-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| AU663725B2 (en) | 1991-08-20 | 1995-10-19 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
| JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| JPH08503855A (ja) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | 嚢胞性線維症に対する遺伝子治療 |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| ATE227979T1 (de) | 1993-04-22 | 2002-12-15 | Skyepharma Inc | Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| EP0694070B1 (en) | 1993-09-15 | 2002-04-10 | Chiron Corporation | Recombinant alphavirus vectors |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| DK0729351T3 (da) | 1993-11-16 | 2000-10-16 | Skyepharma Inc | Vesikler med reguleret afgivelse af aktivstoffer |
| JP4303315B2 (ja) | 1994-05-09 | 2009-07-29 | オックスフォード バイオメディカ（ユーケー）リミテッド | 非交差性レトロウイルスベクター |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| DK0776337T3 (da) | 1994-07-08 | 2005-12-12 | Univ Johns Hopkins Med | Vækstdifferentieringsfaktor-11 |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| DE69739286D1 (de) | 1996-05-06 | 2009-04-16 | Oxford Biomedica Ltd | Rekombinationsunfähige retrovirale vektoren |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| CA2364484A1 (en) | 1999-03-09 | 2000-09-14 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CA2396372A1 (en) | 2000-01-28 | 2001-08-02 | Novo Nordisk A/S | Alkynylsubstituted propionic acid derivatives and their use against diabetes and obesity |
| DE60143798D1 (de) | 2000-06-16 | 2011-02-17 | Cambridge Antibody Tech | Immunspezifisch bindende antikörper gegen blys |
| AU2011244851A1 (en) | 2000-07-27 | 2011-11-24 | The John Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
| US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US8455627B2 (en) | 2001-10-05 | 2013-06-04 | Affimed Therapeutics, Ag | Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa |
| ES2288900T3 (es) | 2001-10-05 | 2008-02-01 | Affimed Therapeutics Ag | Anticuerpo de origen humano para inhibir la agregacion de trombocitos. |
| AR040603A1 (es) | 2002-07-19 | 2005-04-13 | Abbott Lab S A | El uso de un anticuerpo anti-tnfalfa neutralizador de alta afinidad en la fabricacion de un medicamento y conjunto de elementos |
| JP2006507356A (ja) | 2002-09-16 | 2006-03-02 | ワイエス | ミオスタチンのメタロプロテアーゼ活性化およびミオスタチン活性の調節方法 |
| AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US7285269B2 (en) | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| SG153874A1 (en) * | 2003-12-31 | 2009-07-29 | Schering Plough Ltd | Neutralizing epitope-based growth enhancing vaccine |
| EP1729793B1 (en) | 2004-03-02 | 2015-07-22 | Acceleron Pharma Inc. | Alk7 and myostatin inhibitors for muscle wasting disorders |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US20100183695A1 (en) | 2004-05-27 | 2010-07-22 | John Knopf | Cerberus/coco derivatives and uses thereof |
| AU2005271523B2 (en) | 2004-08-03 | 2011-09-15 | Dyax Corp. | hk1-binding proteins |
| WO2006081139A2 (en) | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Antibodies against interleukin-1 beta |
| US20060216279A1 (en) | 2005-03-22 | 2006-09-28 | Glass David J | Myostatin inhibiting fusion polypeptides and therapeutic methods thereof |
| BRPI0610248A2 (pt) * | 2005-04-25 | 2010-06-08 | Pfizer | anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos |
| EP1915397B1 (en) * | 2005-08-19 | 2015-01-14 | Wyeth LLC | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| ES2533464T3 (es) | 2005-10-06 | 2015-04-10 | Eli Lilly And Company | Anticuerpos anti-miostatina |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2007061995A2 (en) | 2005-11-21 | 2007-05-31 | Novartis Ag | Biomarkers for statin-induced myopathy or rhabdomyolysis |
| US8097596B2 (en) | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
| ES2569365T3 (es) | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
| WO2008119426A1 (en) | 2007-03-30 | 2008-10-09 | Merck Patent Gmbh | Birefingent layer with negative optical dispersion |
| CA2688563A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
| TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| UY32341A (es) | 2008-12-19 | 2010-07-30 | Glaxo Group Ltd | Proteínas de unión antígeno novedosas |
| KR101558642B1 (ko) | 2009-02-24 | 2015-10-12 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Ｔｇｆ-베타 슈퍼패밀리의 설계자 리간드 |
| EA027071B1 (ru) | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| ES2993335T3 (en) | 2010-03-10 | 2024-12-27 | Genmab As | Monoclonal antibodies against c-met |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| UY33421A (es) * | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| SG187867A1 (en) * | 2010-08-16 | 2013-03-28 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| US8551892B2 (en) | 2011-07-27 | 2013-10-08 | Asm Japan K.K. | Method for reducing dielectric constant of film using direct plasma of hydrogen |
| CA2852127C (en) | 2011-11-11 | 2020-10-27 | Duke University | Combination drug therapy for the treatment of solid tumors |
| US20130178454A1 (en) | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| WO2013165972A2 (en) | 2012-04-30 | 2013-11-07 | Cell Signaling Technology, Inc. | Anti-hepatitis b virus antibodies and use thereof |
| CN104487453B (zh) | 2012-06-15 | 2018-09-28 | 辉瑞公司 | 经改良的抗gdf-8的拮抗剂抗体及其用途 |
| JP2016500704A (ja) | 2012-11-06 | 2016-01-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 細胞シグナル伝達を変調するための組成物及び方法 |
| SMT202100008T1 (it) * | 2013-05-06 | 2021-03-15 | Scholar Rock Inc | Composizioni e metodi per la modulazione di fattore di crescita |
| EP2853898B1 (en) | 2013-09-27 | 2017-01-04 | Medizinische Hochschule Hannover | Analysis of myostatin in serum |
| EP3068407A1 (en) | 2013-11-11 | 2016-09-21 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety |
| WO2015195094A1 (en) | 2014-06-17 | 2015-12-23 | Ember Therapeutics, Inc. | Anti-activin and nati-myostatin antibodies and methods of using the same |
| EP3215175A4 (en) * | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| WO2016073906A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related immunoassays |
| TWI656133B (zh) | 2014-12-19 | 2019-04-11 | 日商中外製藥股份有限公司 | 抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法 |
| JP6877357B2 (ja) | 2015-04-15 | 2021-05-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法 |
| IL305148A (en) * | 2015-09-15 | 2023-10-01 | Scholar Rock Inc | Anti-pro/hidden myostatin antibodies and their uses |
| JP2019504064A (ja) * | 2016-01-08 | 2019-02-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型ミオスタチン抗体およびその使用方法 |
| EP3785728A3 (en) | 2016-06-13 | 2021-04-28 | Scholar Rock, Inc. | Use of myostatin inhibitors and combination therapies |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| JP7198757B2 (ja) | 2017-01-06 | 2023-01-04 | スカラー ロック インコーポレイテッド | ミオスタチン活性化の阻害により代謝疾患を処置するための方法 |
-
2016
- 2016-09-15 IL IL305148A patent/IL305148A/en unknown
- 2016-09-15 AU AU2016323447A patent/AU2016323447B2/en active Active
- 2016-09-15 HR HRP20250666TT patent/HRP20250666T1/hr unknown
- 2016-09-15 PL PL16774748T patent/PL3350220T3/pl unknown
- 2016-09-15 EP EP21170667.6A patent/EP3922645B1/en active Active
- 2016-09-15 FI FIEP21170667.6T patent/FI3922645T3/fi active
- 2016-09-15 EP EP24201758.0A patent/EP4461312A3/en active Pending
- 2016-09-15 CN CN202111206951.0A patent/CN113912718B/zh active Active
- 2016-09-15 IL IL258121A patent/IL258121B2/en unknown
- 2016-09-15 LT LTEP16774748.4T patent/LT3350220T/lt unknown
- 2016-09-15 KR KR1020237037152A patent/KR102773636B1/ko active Active
- 2016-09-15 CN CN202111206744.5A patent/CN113896789B/zh active Active
- 2016-09-15 MX MX2018003196A patent/MX2018003196A/es unknown
- 2016-09-15 LT LTEP21170667.6T patent/LT3922645T/lt unknown
- 2016-09-15 SM SM20210432T patent/SMT202100432T1/it unknown
- 2016-09-15 KR KR1020257005821A patent/KR20250033313A/ko active Pending
- 2016-09-15 RS RS20210987A patent/RS62330B1/sr unknown
- 2016-09-15 ES ES16774748T patent/ES2881642T3/es active Active
- 2016-09-15 SI SI201631904T patent/SI3922645T1/sl unknown
- 2016-09-15 US US15/760,393 patent/US10751413B2/en active Active
- 2016-09-15 RS RS20250592A patent/RS66913B1/sr unknown
- 2016-09-15 PT PT211706676T patent/PT3922645T/pt unknown
- 2016-09-15 CN CN202111206864.5A patent/CN113896790B/zh active Active
- 2016-09-15 DK DK21170667.6T patent/DK3922645T3/da active
- 2016-09-15 SI SI201631287T patent/SI3350220T1/sl unknown
- 2016-09-15 HU HUE21170667A patent/HUE072064T2/hu unknown
- 2016-09-15 HR HRP20211081TT patent/HRP20211081T1/hr unknown
- 2016-09-15 PL PL21170667.6T patent/PL3922645T3/pl unknown
- 2016-09-15 CA CA3036652A patent/CA3036652A1/en active Pending
- 2016-09-15 SM SM20250263T patent/SMT202500263T1/it unknown
- 2016-09-15 BR BR112018004981-6A patent/BR112018004981A2/pt active Search and Examination
- 2016-09-15 WO PCT/US2016/052014 patent/WO2017049011A1/en not_active Ceased
- 2016-09-15 CN CN201680065184.7A patent/CN108350067B/zh active Active
- 2016-09-15 PT PT167747484T patent/PT3350220T/pt unknown
- 2016-09-15 HU HUE16774748A patent/HUE055331T2/hu unknown
- 2016-09-15 ES ES21170667T patent/ES3030258T3/es active Active
- 2016-09-15 EA EA201890712A patent/EA038146B1/ru unknown
- 2016-09-15 KR KR1020187010090A patent/KR102596852B1/ko active Active
- 2016-09-15 EP EP16774748.4A patent/EP3350220B1/en active Active
- 2016-09-15 DK DK16774748.4T patent/DK3350220T3/da active
- 2016-09-15 JP JP2018513591A patent/JP7107836B2/ja active Active
-
2018
- 2018-03-14 MX MX2022005173A patent/MX2022005173A/es unknown
- 2018-03-14 CO CONC2018/0002703A patent/CO2018002703A2/es unknown
- 2018-03-14 MX MX2022005211A patent/MX2022005211A/es unknown
- 2018-03-14 MX MX2022005202A patent/MX2022005202A/es unknown
- 2018-03-14 MX MX2022005177A patent/MX2022005177A/es unknown
-
2020
- 2020-06-24 US US16/946,483 patent/US11439704B2/en active Active
-
2021
- 2021-08-10 CY CY20211100716T patent/CY1124619T1/el unknown
-
2022
- 2022-07-12 JP JP2022111605A patent/JP7418508B2/ja active Active
-
2023
- 2023-06-21 AU AU2023203922A patent/AU2023203922A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000878A patent/JP7785107B2/ja active Active
-
2025
- 2025-11-27 JP JP2025205441A patent/JP2026035721A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3350220T3 (pl) | Przeciwciała przeciwko pro/latentnej miostatynie i ich zastosowania | |
| IL262095A (en) | Anti-pacap antibodies and uses thereof | |
| PL3383916T3 (pl) | Przeciwciała anty-cd73 i ich zastosowania | |
| IL264011A (en) | Antibodies against tim3 and uses thereof | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| PL3280441T3 (pl) | Przeciwciała przeciwko sortilinie i sposoby ich stosowania | |
| PL3295951T3 (pl) | Przeciwciała anty-pvrig i sposoby ich zastosowania | |
| IL259747A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| IL255949A (en) | Antibodies against ox40 and uses thereof | |
| PL4234581T3 (pl) | Przeciwciała terapeutyczne i ich zastosowania | |
| IL257324A (en) | Antibody against glypican-3 and application thereof | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| PL3274370T3 (pl) | Przeciwciała anty-ceacam6 i ich zastosowania | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| PT3443009T (pt) | Anticorpos anti-tim-3 e composições | |
| PL3380522T3 (pl) | Cząsteczki przeciwciał wobec april i ich zastosowania | |
| HUE045307T2 (hu) | EGFRVIII-ellenes antitestek és alkalmazásaik | |
| HUE048284T2 (hu) | Anti-CD40 antitestek és alkalmazásuk | |
| PL3250610T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| IL263273A (en) | Anti-gitr antibodies and uses thereof | |
| IL258079B (en) | Antigen receptors and uses thereof | |
| PL3280440T3 (pl) | Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania | |
| PL3319612T3 (pl) | Oksysterole i sposoby ich stosowania | |
| IL262251B1 (en) | New anti-sirpa antibodies and their therapeutic applications | |
| IL271398A (en) | Anti-l1-cam antibodies and uses thereof |